Extension of Time to File SOU

PTO- 1581

Approved for use through 03/31/2024. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1581

Approved for use through 03/31/2024. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: VUITY (see, http://uspto.report/TM/88781212/mark.png)
SERIAL NUMBER: 88781212

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Allergan Sales, LLC, having an address of
      5 Giralda Farms
      Madison, New Jersey 07940
      United States
      Email: XXXX
Proposed: Allergan Sales, LLC, having an address of
      5 Giralda Farms
      Madison, New Jersey 07940
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 12/29/2020.

For International Class 005:
Current identification: Solutions for the treatment of presbyopia

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

Correspondence Information (current):
      Allergan Sales, LLC
      PRIMARY EMAIL FOR CORRESPONDENCE: annie.chen@allergan.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): matthew.brady@allergan.com

Correspondence Information (proposed):
      Cheryl A. Withycombe
      PRIMARY EMAIL FOR CORRESPONDENCE: cheryl.withycombe@abbvie.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): trademarks@abbvie.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

The applicant hereby appoints Cheryl A. Withycombe of  AbbVie Inc.
      2525 Dupont Drive
      Irvine, California 92612
      United States


      The phone number is 8479373386.

      The fax number is 8479382623.
      PRIMARY EMAIL: cheryl.withycombe@abbvie.com
      SECONDARY EMAIL: NOT PROVIDED
to submit this Request for Extension of Time to File a Statement of Use on behalf of the applicant.



A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Cheryl A. Withycombe/      Date Signed: 06/18/2021
Signatory's Name: Cheryl A. Withycombe
Signatory's Position: Attorney of Record/CA Bar Member
Signatory's Phone: 847-937-3386
Signature method: Sent to third party for signature

Mailing Address:
   AbbVie Inc.
   
   2525 Dupont Drive
   Irvine, California 92612

PAYMENT: 88781212
PAYMENT DATE: 06/21/2021

Serial Number: 88781212
Internet Transmission Date: Mon Jun 21 10:01:11 ET 2021
TEAS Stamp: USPTO/ESU-XXX.XXX.XXX.XX-202106211001111
01646-88781212-780d59d677195d7762482da38
9b15daf553e55ed75acd1aa577ad478ce87612c6
e-DA-01084021-20210616121412572727